MULTIPLE SCLEROSIS MARKET OUTLOOK 2032 | Immune Response BioPharma Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alk

MULTIPLE SCLEROSIS MARKET OUTLOOK 2032 | Immune Response BioPharma Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alk
The Multiple Sclerosis Market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.

The Multiple Sclerosis (MS) market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies such as NeuroVax (Immune Response BioPharma), CNM-Au8 (Clene Nanomedicine), and others. Moreover, the rising research & development activities and growing prevalence of Multiple Sclerosis are also anticipated to fuel the market growth during the forecast period.

The Multiple Sclerosis treatment market looks promising as the market is emerging and continuously evolving with various newer treatments that the FDA has recently designated to treat the disease. However, large multicenter trials are still necessary to examine the overarching patterns of Multiple Sclerosis and treatment response as a whole. Overall, the increasing prevalence of the disease, along with upcoming novel therapies and increasing awareness, will fuel the market in the coming years.

DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Sclerosis market size, share, and trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

The Multiple Sclerosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Multiple Sclerosis Overview

Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, including the brain, spinal cord, and optic nerves. It is characterized by inflammation, demyelination (damage to the protective covering of nerve fibers), and scarring (sclerosis) within the CNS.

Multiple Sclerosis Market Key Facts

  • The Multiple Sclerosis market size in the seven major markets was found to be USD 22,381 million in 2020.
  • The total prevalent cases of Multiple Sclerosis were 1,265,000+ in 2020 in the 7MM.
  • As per DelveInsight’s estimates, in 2019, the prevalent cases of Multiple Sclerosis in the United States were found to be 708,000+ cases which will increase by 2032.
  • The prevalent population of Multiple Sclerosis in Japan in 2019 was found to be 4,800+.
  • According to DelveInsight’s estimates, the prevalence of Multiple Sclerosis is higher in females as compared to males.
  • With the continuous efforts in research and development, various companies are developing new therapies for the treatment of Multiple Sclerosis, some of which include NeuroVax (Immune Response BioPharma, Inc.), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), Ublituximab (TG Therapeutics, Inc.), ALKS 8700 (Alkermes/Biogen), Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical), Masitinib (AB Science), Fenebrutinib (Genentech), and others.

Multiple Sclerosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Multiple Sclerosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Multiple Sclerosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Multiple Sclerosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Multiple Sclerosis Epidemiology, Segmented by –

  • Total Prevalent Cases of Multiple Sclerosis in the 7MM (2019–2032)
  • Phenotype-specific prevalent cases of Multiple Sclerosis in the 7MM (2019–2032)
  • Prevalence of Multiple Sclerosis based on Age in the 7MM (2019–2032)
  • Prevalence of Multiple Sclerosis based on Gender in the 7MM (2019–2032)
  • EDSS in the 7MM (2019–2032)

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched during the study period. The analysis covers the Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Multiple Sclerosis Market Will Evolve by 2032 @

Some of the Leading Companies in the Multiple Sclerosis Therapeutics Market Include:

  • Immune Response BioPharma, Inc.
  • Clene Nanomedicine
  • Sanofi
  • Merck Healthcare KGaA
  • TG Therapeutics, Inc.
  • Apimeds Inc.
  • Bayer HealthCare
  • Novartis
  • Biogen
  • Alkermes
  • Genentech
  • And Many Others

Multiple Sclerosis Emerging Drugs Covered in the Report Include:

  • NeuroVax (Immune Response BioPharma, Inc.)
  • CNM-Au8 (Clene Nanomedicine)
  • Tolebrutinib (SAR442168) (Sanofi)
  • Evobrutinib/M2951 (Merck Healthcare KGaA)
  • Ublituximab (TG Therapeutics, Inc.)
  • ALKS 8700 (Alkermes/Biogen)
  • Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical)
  • Masitinib (AB Science)
  • Fenebrutinib (Genentech)
  • And Many Others

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:

Table of Contents

1. Key Insights

2. Executive Summary 

3. Multiple Sclerosis Competitive Intelligence Analysis

4. Multiple Sclerosis Market Overview at a Glance

5. Multiple Sclerosis Disease Background and Overview

6. Multiple Sclerosis Patient Journey

7. Multiple Sclerosis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Sclerosis Unmet Needs

10. Key Endpoints of Multiple Sclerosis Treatment

11. Multiple Sclerosis Marketed Products

12. Multiple Sclerosis Emerging Drugs and Latest Therapeutic Advances

13. Multiple Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Sclerosis Market Outlook (In US, EU5, and Japan)

16. Multiple Sclerosis Access and Reimbursement Overview

17. KOL Views on the Multiple Sclerosis Market

18. Multiple Sclerosis Market Drivers

19. Multiple Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States